Brookline Capital Markets Downgrades Hepion Pharma (HEPA) to Hold
Tweet
Share
E-mailGet Alerts HEPA Hot Sheet
Price: $0.32 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Brookline Capital Markets analyst Kumaraguru Raja downgraded Hepion Pharma (NASDAQ: HEPA) from Buy to Hold.
For an analyst ratings summary and ratings history on Hepion Pharma click here. For more ratings news on Hepion Pharma click here.
Shares of Hepion Pharma closed at $3.24 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
